Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

Description

Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without diabetes that fasting can be detrimental to the hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, the impact fasting has on hypoglycemic counterregulation in people with T1D will be determined.

Conditions

Hypoglycemia, Type1diabetes

Talk to us

Study Overview

On this page

Study Details

Study overview

Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without diabetes that fasting can be detrimental to the hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, the impact fasting has on hypoglycemic counterregulation in people with T1D will be determined.

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

Condition
Hypoglycemia
Intervention / Treatment

-

Contacts and Locations

Cincinnati

University of Cincinnati, Cincinnati, Ohio, United States, 45267-0547

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * males and females of any race or ethnicity
  • * non-obese (BMI \< or = to 30)
  • * have a diagnosis of type 1 diabetes
  • * C-peptide negative
  • * pregnant women
  • * cigarette smoking
  • * Taking inflammation-targeting steroids (e.g., prednisone).
  • * Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).
  • * Hematocrit less than 33%.
  • * Presence of HIV or hepatitis (due to their deleterious effects on the liver).
  • * The presence of cardiovascular or peripheral vascular disease.
  • * The presence of neuropathy, retinopathy or nephropathy.
  • * A detection of the presence of any other disease or condition by one of the study doctors, that would be expected to confound the responses to insulin-induced hypoglycemia or make participation in the study dangerous to the individual.

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Cincinnati,

Study Record Dates

2024-12-31